Reiter Edward O, Norjavaara Ensio
Department of Pediatrics, Baystate Children's Hospital, Tufts University School of Medicine, Springfield, MA 01199, USA.
Pediatr Endocrinol Rev. 2005 Dec;3(2):77-86.
Testotoxicosis is a form of gonadotropin-independent (peripheral) precocious puberty in which boys experience early onset and progression of puberty. Patients have accelerated growth, early development of secondary sexual characteristics and usually reduced adult height. Testotoxicosis is caused by an activating mutation of the luteinizing hormone (LH) receptor, leading to increased levels of sex steroids in the context of low LH. Therapy has, therefore, traditionally targeted steroidogenesis. However, the drugs used have been associated with side effects. More recently, a combination of an oral anti-androgen (spironolactone) and an aromatase inhibitor (testolactone) decreased height velocity and improved predicted height. A phase II study in testotoxicosis is currently underway,exploring the combination of a highly selective anti-androgen, bicalutamide, and the potent aromatase inhibitor, anastrozole. These agents are well tolerated in the populations in which they have been studied and effectively inhibit testosterone activity and estrogen production, in adult patients.
睾丸中毒症是一种促性腺激素非依赖性(外周性)性早熟,患病男孩青春期提前开始并进展。患者生长加速,第二性征过早发育,成年身高通常降低。睾丸中毒症由促黄体生成素(LH)受体的激活突变引起,导致在低LH水平情况下性类固醇水平升高。因此,传统治疗针对类固醇生成。然而,所使用的药物存在副作用。最近,口服抗雄激素药物(螺内酯)和芳香化酶抑制剂(睾酮内酯)联合使用降低了身高增长速度并改善了预测身高。目前正在进行一项关于睾丸中毒症的II期研究,探索高选择性抗雄激素药物比卡鲁胺和强效芳香化酶抑制剂阿那曲唑的联合使用。这些药物在所研究的人群中耐受性良好,并且在成年患者中能有效抑制睾酮活性和雌激素生成。